Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.
Addington J, Liu L, Braun A, Auther A, Calkins ME, Cornblatt BA, Corcoran CM, Fusar-Poli P, Kerr MJ, Mourgues-Codern CV, Nunez AR, Oliver D, Strauss GP, Walsh BC, Alameda LK, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Carrion RE, Chen EYH, Choi J, Coleman MJ, Conus P, Diaz-Caneja CM, Dwyer D, Ellman LM, Faghankhani M, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui C, Jacobs GR, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Marcy PJ, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Penzel N, Perez J, Perkins DO, Powers AR 3rd, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Thompson A, Thompson JL, Upthegrove R, Verma S, Wang J, Wastler HM, Wickham A, Rossum IW, Wolf DH, Bouix S, Pasternak O, Kahn RS, Bearden CE, Kane JM, McGorry PD, Buccilli K, Nelson B, Shenton ME, Woods SW; Accelerating Medicines Partnership® -Schizophrenia; Yung AR.
Addington J, et al. Among authors: langbein k.
Schizophrenia (Heidelb). 2025 Apr 3;11(1):54. doi: 10.1038/s41537-025-00556-7.
Schizophrenia (Heidelb). 2025.
PMID: 40180953
Free PMC article.
